Was ist neu bei Kollagenosen?

Schlüsselwörter

Lupus erythematodes - systemische Sklerose - Dermatomyositis

Keywords

lupus erythematosus - systemic sclerosis - dermatomyositis

• Literatur

• 1 Adler S, Koerner M, Foerger F et al. Histological, Serological and clinical changes in response to abatacept treatment of Sjögren’s syndrome. . ACR Kongress 2012, Abstract 2553. http://www.acrannualmeeting.org/
• 2 Allenbach Y, Rigolet A, Guiguet M et al. Efficacy of rituximab for the treatment of refractory inflammatory myopathies associated with anti-histidyl-tRNA synthetase antibodies (the FORCE Jo1 Study). . ACR Kongress 2012, Abstract 220. http://www.acrannualmeeting.org/
• 3 Burt RK, Shah SJ, Dill K et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis ASSIST): an open-label, randomisedphase 2 trial. Lancet 2011; 378: 498-506
• 4 Devauchelle-Pensec V, Mariette X, Jousse-Joulin S et al. Tolerance and efficacy in primary Sjogren syndrome: final results of a randomized controlled trial. . ACR Kongress 2012, Abstract 2554. http://www.acrannualmeeting.org/
• 5 Gordon JK, Davids ML, Doobay K et al. Nilotinib in the treatment of early diffuse systemic sclerosis: a single group label pilot clinical trial.. . ACR Kongress 2012 Abstract 694. http://www.acrannualmeeting.org/
• 6 Higgs BW, Zhu W, Salvin S et al. Results of the Beliss Study, the first open phase 2 study of belimumab in primary Sjögren’s syndrome. . ACR Kongress 2012, Abstract 755. http://www.acrannualmeeting.org/
• 7 Hobbs K, Wallace DJ, Morehouse C et al. Sifalimumab, an anti-IFN-alpha monoclonal antibody shows target suppression of a type I IFN signature in blood and muscle of dermatomyositis and polymyositis patients. . ACR Kongress 2012, Abstract 639 http://www.acrannualmeeting.org/
• 8 Izmirly PM, Costedoat-Chalumeau N, Pisoni CN et al. Maternal use of hydroxychloroquine is assiciated with a reduced risk of recurrent anti-SSA/Ro-eantibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126: 76-82
• 9 Kalunian K, Merrill JT, Maciuca R et al. Efficacy and safety of rontalizumab (anti-interferon alpha) in SLE subjects with restricted immunosuppressant use: results of a randomized, double-blind, placebo-controlled phase 2 study. . ACR Kongress 2012, Abstract 2622. http://www.acrannualmeeting.org/
• 10 Lorenz H. Kollagenosen. Dtsch med Wochenschr 2012; 137: 661-663
• 11 Malik A, Aggarwal R, Qi Z et al. Hydroxy-3-Methylglutaryl-coenzyme A reductase (HMGCoR) antibody in necrotizing myopathy and the role of statins. . ACR Kongress 2012, Abstract 230. http://www.acrannualmeeting.org/
• 12 Mammen AL, Chung T, Christopher-Stine L et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63: 713-721
• 13 Mariette X, Quartuccio L, Salvin S et al. Results of the Beliss Study, the first open phase 2 study of belimumab in primary Sjögren’s syndrome. . ACR Kongress 2012, Abstract 2555. http://www.acrannualmeeting.org/
• 14 Merrill JT, Ginzler EM, Wallace DJ et al. LBSL02/99 Study Group. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematodes. Arthritis Rheum 2012; 64: 3364-3373
• 15 Oddis CV, Reed AM, Aggarwal R et al. Rituximab in Myositis (RIM) Study Group: Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 02.11.2012; doi: [Epub ahead of print]
• 16 Ruiz-Arruza I, Gladman DD, Ibanez D, Urowitz MB. Antimalarial protect Systemic lupus erythematosus patients from damage accrual during the first five years of the disease. . ACR Kongress 2012, Abstract 1421 http://www.acrannualmeeting.org/
• 17 van Laar JM, Farge D, Sont JK et al. High Dose immunoablation and autologous hematopoetic stem cell transplantation versus monthly intravenous pulse therapy Cyclophosphamide in severe systemic sclerosis. . ACR Kongress 2012, Abstract L2. http://www.acrannualmeeting.org/
• 18 Wang D, Zhang H, Liang J et al. Allogenic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years experience. Cell Transplant 31.10.2012; [Epub ahead of print]